SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

ARGX

534.2

-1.62%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

ARGX

534.2

-1.62%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

ARGX

534.2

-1.62%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

ARGX

534.2

-1.62%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

ARGX

534.2

-1.62%↓

PHIA

22.93

-2.43%↓

Search

Fresenius SE & Co KGaA

Closed

SectorHealthcare

39.42 -0.45

Overview

Share price change

24h

Current

Min

38.45

Max

39.6

Key metrics

By Trading Economics

Income

-55M

264M

Sales

264M

5.6B

P/E

Sector Avg

48.146

63.778

Profit margin

4.689

Employees

176,486

EBITDA

-33M

724M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+14.99% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

1.4B

22B

Previous open

39.87

Previous close

39.42

News Sentiment

By Acuity

56%

44%

307 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Fresenius SE & Co KGaA Chart

Past performance is not a reliable indicator of future results.

Related News

26 Feb 2025, 13:37 UTC

Market Talk

European Stocks on Track for Record Close as Earnings Lift Mood -- Market Talk

5 Jun 2024, 12:18 UTC

Market Talk

Fresenius Helios Guidance Lift Should Drive Consensus Upgrades -- Market Talk

Peer Comparison

Price change

Fresenius SE & Co KGaA Forecast

Price Target

By TipRanks

14.99% upside

12 Months Forecast

Average 45.4 EUR  14.99%

High 48 EUR

Low 42 EUR

Based on 12 Wall Street analysts offering 12 month price targets forFresenius SE & Co KGaA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

39.31 / 40.17Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

307 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.